Last reviewed · How we verify
Semaglutide Administered SC — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Semaglutide Administered SC (Semaglutide Administered SC) — BrightGene Bio-Medical Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Semaglutide Administered SC TARGET | Semaglutide Administered SC | BrightGene Bio-Medical Technology Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Semaglutide Administered SC CI watch — RSS
- Semaglutide Administered SC CI watch — Atom
- Semaglutide Administered SC CI watch — JSON
- Semaglutide Administered SC alone — RSS
Cite this brief
Drug Landscape (2026). Semaglutide Administered SC — Competitive Intelligence Brief. https://druglandscape.com/ci/semaglutide-administered-sc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab